CorMedix Q2 revenue $101.9M, net income $26.0M; raises FY26 adjusted EBITDA guidance

CorMedix Inc.

Q2 2026 consolidated revenue of $101.9M; net income of $26.0M; adjusted EBITDA of $58.7M; diluted EPS $0.29.
DefenCath net revenue $66.1M; acquired Melinta portfolio contributed $35.8M.
FY26 revenue guidance maintained at $325-345M; adjusted EBITDA guidance raised to $125-140M.
New multi-year DefenCath supply agreement with an LDO; now covers all top 5 U.S. dialysis providers.
REZZAYO sNDA for prophylaxis of invasive fungal disease expected Q3 2026; FDA action anticipated H1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.